Suppr超能文献

在进展中的和破裂的人冠状动脉和颈动脉粥样硬化病变中氧化特异性表位和载脂蛋白(a)的差异表达。

Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions.

机构信息

CVPath Institute, Gaithersburg, MD, USA.

出版信息

J Lipid Res. 2012 Dec;53(12):2773-90. doi: 10.1194/jlr.P030890. Epub 2012 Sep 11.

Abstract

The relationships between oxidation-specific epitopes (OSE) and lipoprotein (a) [Lp(a)] and progressive atherosclerosis and plaque rupture have not been determined. Coronary artery sections from sudden death victims and carotid endarterectomy specimens were immunostained for apoB-100, oxidized phospholipids (OxPL), apo(a), malondialdehyde-lysine (MDA), and MDA-related epitopes detected by antibody IK17 and macrophage markers. The presence of OxPL captured in carotid and saphenous vein graft distal protection devices was determined with LC-MS/MS. In coronary arteries, OSE and apo(a) were absent in normal coronary arteries and minimally present in early lesions. As lesions progressed, apoB and MDA epitopes did not increase, whereas macrophage, apo(a), OxPL, and IK17 epitopes increased proportionally, but they differed according to plaque type and plaque components. Apo(a) epitopes were present throughout early and late lesions, especially in macrophages and the necrotic core. IK17 and OxPL epitopes were strongest in late lesions in macrophage-rich areas, lipid pools, and the necrotic core, and they were most specifically associated with unstable and ruptured plaques. Specific OxPL were present in distal protection devices. Human atherosclerotic lesions manifest a differential expression of OSEs and apo(a) as they progress, rupture, and become clinically symptomatic. These findings provide a rationale for targeting OSE for biotheranostic applications in humans.

摘要

氧化特异性表位(OSE)与脂蛋白(a)[Lp(a)]与进行性动脉粥样硬化和斑块破裂之间的关系尚未确定。用抗apoB-100、氧化磷脂(OxPL)、apo(a)、丙二醛-赖氨酸(MDA)和 MDA 相关表位抗体 IK17 对猝死者的冠状动脉切片和颈动脉内膜切除术标本进行免疫染色,并对巨噬细胞标志物进行染色。通过 LC-MS/MS 确定在颈动脉和隐静脉移植远端保护装置中捕获的 OxPL 的存在。在冠状动脉中,正常冠状动脉中不存在 OSE 和 apo(a),早期病变中存在少量 OSE 和 apo(a)。随着病变的进展,apoB 和 MDA 表位没有增加,而巨噬细胞、apo(a)、OxPL 和 IK17 表位则相应增加,但它们根据斑块类型和斑块成分而有所不同。apo(a)表位存在于早期和晚期病变中,尤其是在巨噬细胞和坏死核心中。IK17 和 OxPL 表位在富含巨噬细胞的区域、脂质池和坏死核心的晚期病变中最强,它们与不稳定和破裂的斑块最密切相关。在远端保护装置中存在特定的 OxPL。人类动脉粥样硬化病变在进展、破裂和出现临床症状时表现出 OSE 和 apo(a)的差异表达。这些发现为针对 OSE 进行生物治疗和诊断应用提供了依据。

相似文献

引用本文的文献

2
Oxidized phospholipid damage signals as modulators of immunity.氧化磷脂损伤信号作为免疫调节剂
Open Biol. 2025 Jul;15(7):240391. doi: 10.1098/rsob.240391. Epub 2025 Jul 30.
4
Lipoprotein(a) and cardiovascular disease.脂蛋白(a)与心血管疾病。
Biochem J. 2024 Oct 2;481(19):1277-1296. doi: 10.1042/BCJ20240037.
5
Tipping the Scale: Atheroprotective IgM-Producing B Cells in Atherosclerosis.颠覆传统:动脉粥样硬化中的抗动脉粥样硬化 IgM 产生 B 细胞。
Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):1906-1915. doi: 10.1161/ATVBAHA.124.319847. Epub 2024 Jul 18.
6
Therapeutic Potential of Lipoprotein(a) Inhibitors.脂蛋白(a)抑制剂的治疗潜力。
Drugs. 2024 Jun;84(6):637-643. doi: 10.1007/s40265-024-02046-z. Epub 2024 Jun 8.
7
High lipoprotein(a): Actionable strategies for risk assessment and mitigation.高脂蛋白(a):风险评估与缓解的可行策略
Am J Prev Cardiol. 2024 Apr 3;18:100651. doi: 10.1016/j.ajpc.2024.100651. eCollection 2024 Jun.
8
Lipoprotein(a), platelet function and cardiovascular disease.脂蛋白(a)、血小板功能与心血管疾病。
Nat Rev Cardiol. 2024 May;21(5):299-311. doi: 10.1038/s41569-023-00947-2. Epub 2023 Nov 8.
10
Oxidized phospholipids in cardiovascular disease.氧化磷脂在心血管疾病中的作用。
Nat Rev Cardiol. 2024 Mar;21(3):170-191. doi: 10.1038/s41569-023-00937-4. Epub 2023 Oct 17.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验